Arch Biopartners Stock Probability of Future Stock Price Finishing Under 1.04

ARCH Stock  CAD 1.96  0.01  0.51%   
Arch Biopartners' future price is the expected price of Arch Biopartners instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Arch Biopartners performance during a given time horizon utilizing its historical volatility. Check out Arch Biopartners Backtesting, Arch Biopartners Valuation, Arch Biopartners Correlation, Arch Biopartners Hype Analysis, Arch Biopartners Volatility, Arch Biopartners History as well as Arch Biopartners Performance.
  
Please specify Arch Biopartners' target price for which you would like Arch Biopartners odds to be computed.

Arch Biopartners Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Arch Biopartners for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Arch Biopartners can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Arch Biopartners may become a speculative penny stock
Arch Biopartners has accumulated 5.02 M in total debt. Arch Biopartners has a current ratio of 0.31, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Arch Biopartners until it has trouble settling it off, either with new capital or with free cash flow. So, Arch Biopartners' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Arch Biopartners sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Arch to invest in growth at high rates of return. When we think about Arch Biopartners' use of debt, we should always consider it together with cash and equity.
The entity reported the revenue of 1.98 M. Net Loss for the year was (3.33 M) with loss before overhead, payroll, taxes, and interest of (502.88 K).
Arch Biopartners has accumulated about 72.82 K in cash with (234.07 K) of positive cash flow from operations.
Roughly 20.0% of the company shares are held by company insiders

Arch Biopartners Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Arch Stock often depends not only on the future outlook of the current and potential Arch Biopartners' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Arch Biopartners' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding62.5 M
Cash And Short Term Investments831.3 K

Arch Biopartners Technical Analysis

Arch Biopartners' future price can be derived by breaking down and analyzing its technical indicators over time. Arch Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Arch Biopartners. In general, you should focus on analyzing Arch Stock price patterns and their correlations with different microeconomic environments and drivers.

Arch Biopartners Predictive Forecast Models

Arch Biopartners' time-series forecasting models is one of many Arch Biopartners' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Arch Biopartners' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Arch Biopartners

Checking the ongoing alerts about Arch Biopartners for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Arch Biopartners help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Arch Biopartners may become a speculative penny stock
Arch Biopartners has accumulated 5.02 M in total debt. Arch Biopartners has a current ratio of 0.31, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Arch Biopartners until it has trouble settling it off, either with new capital or with free cash flow. So, Arch Biopartners' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Arch Biopartners sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Arch to invest in growth at high rates of return. When we think about Arch Biopartners' use of debt, we should always consider it together with cash and equity.
The entity reported the revenue of 1.98 M. Net Loss for the year was (3.33 M) with loss before overhead, payroll, taxes, and interest of (502.88 K).
Arch Biopartners has accumulated about 72.82 K in cash with (234.07 K) of positive cash flow from operations.
Roughly 20.0% of the company shares are held by company insiders

Additional Tools for Arch Stock Analysis

When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.